Study to Determine the Safety and Efficacy of Teneligliptin (20 Mg) in Naive Type 2 Diabetes Mellitus
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2023, Vol 3, Issue 3
Abstract
Background: Teneligliptin is a novel, highly selective DPP-4 inhibitor with long half-life, approved in Japan (2012) and in Korea (2014) to treat patients of type 2 DM. It is characterized by a considerably rigid structure formed by five consecutive rings.Teneligliptin, 20mg/day as monotherapy and combination therapy in type 2 DM was shown to be effective in reducing HbA1c and fasting plasma glucose levels without any significant adverse events. Present study was conducted to determine the safety and efficacy of Teneligliptin (20 mg) in naive type 2 diabetes mellitus. Materials and methods:The present study was a hospital based prospective study undertaken to study the safety and efficacy of teneligliptin (20 mg) in naïve type 2 diabetes mellitus. Newly diagnosed type 2 diabetes mellitus patients within age group 18-70 years were studied. All patients were assessed for Blood sugar levels (Fasting and Postprandial HbA1C, Serum urea, Serum Creatinine, Serum uric acid, Lipid profile and ECG. Results: The mean age of total patients was 52.86 ±9.24 years. The mean HbA1c among patients with DM was 7.76 ±1.61. The mean serum urea was 29.12±6.58mg/dl while Serum creatinine was 1.08±0.18 mg/dl. The mean fasting Blood sugar of the patients before treatment was 123.55 ±10.72 and 103.12 ±8.63 mg/dl after treatment with statistical significant difference (p<0.05). The mean blood urea of the patients before treatment was 29.12 ±6.58 and 20.86 ±5.04 mg/dl after treatment with no statistical significant difference. (p >0.05) The mean QT interval of the patients before treatment was 0.37±0.03 and 0.38±0.03 seconds after treatment with statistical non-significant difference (p <0.05). Conclusion: The present study concludes that, Teneligliptin, a novel DPP-4I, when prescribed as a monotherapy antidiabetic agent in a dose of 20 mg daily, significantly improved glycemic parameters. The results of this study suggest that teneligliptin can be considered to be an effective antidiabetic agent in the management of Indian patients with type naive 2 Diabetes Mellitus.
Authors and Affiliations
Subhash Chandra , Pulkit Chaudhary , Vagish Baranwal
Keywords
Related Articles
- EP ID EP739963
- DOI 10.47191/ijmscrs/v3-i3-40
- Views 44
- Downloads 0
Prevalence and Triggering Factors Associated with Mobile Phone Addiction among University Students in Bangladesh
BACKGROUND: Nowadays, mobile phones are constantly being improved by enlarging upon their functionalities, which in turn increases the tendency of overuse and addiction. This study aimed to find the prevalence and factor...
Internists' Satisfaction with Clinical Laboratories Services of Basra City: A Pilot Study
BACKGROUND:The quality of laboratory services is a very important tool for patient care. Medical decisions in diagnosing disease and providing appropriate treatment mainly depends on the results of laboratory tests joint...
Covid -19 Pandemic Disease
Covid-19 is one of the pandemic diseaseswhich was widely spread all over the world. Nowthe new mutated variant strain, Deltaplus, may cause a third wave of thecoronavirus.So,allof themare worried about...
Innocent Murmur since Childhood: Elderly Patient with Undiagnosed Interventricular Septal Defect
Ventricularseptal defects in adulthood only accountfor10 per centof congenital heart defects, In patients with evidence of LV volume overloadand no Pulmonary Arterial Hypertension(no non-invasive signs of Pulmo...
Periosteal Incarceration in the Growth Plate: A Rare Association in Epiphyseal Detachment Fractures
Growth cartilage is a pivotal area between the epiphysis and the metaphysis, with relative fragility. She was incarcerated for soft tissue during a Salter-Harris type I epiphysic detachment in a 13-year-old girl. Such a...